Sanofi with success Dear an inaugural sustainability bond indexed on access to drugs
Paris, March 312022. Sanofi successfully priced yesterday, March 30, 2022, its offering of bonds in two tranches of €1.5 billion (the “Bonds”). It includes an inaugural sustainability bond issue with a nominal amount of €650 million of bonds, linked to Sanofi’s commitment to improving access to essential medicines in low-income countries and intermediary through its nonprofit Global Health Unit. This transaction demonstrates Sanofi’s societal commitment to ensuring access to healthcare for vulnerable people around the world.
Jean-Baptiste de Chatillon
Chief Financial Officer of Sanofi
“One year after pioneering sustainable finance with our sustainability-linked revolving credit facilities, we are further contributing to the development of the sustainable finance market with the successful pricing of our first sustainability-linked bond” said Jean-Baptiste de Chatillon, chief financial officer of Sanofi. “We continue to make progress in our environmental, social and governance activities which are an essential part of our strategy and integrated into our business.”
The Notes consist of two sections:
- €850 million of fixed-rate bonds, maturing April 2025, bearing interest at an annual rate of 0.875%.
- €650 million of fixed rate bonds, due April 2029, bearing interest at an annual rate of 1.250%. Voucher amounts are linked to the achievement of a sustainability performance target defined as the cumulative number of patients, i.e. at least 1.5 million patients, receiving essential medicines by the global health unit, for the treatment non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026.
Sandrine Bouttier Stref
Global Head of Corporate Social Responsibility at Sanofi
“Linking the cost of financing to the achievement of concrete objectives in terms of access to medicines confirms our desire to put social responsibility at the center of our ambitions..”
Sanofi’s broader social impact strategy aims to build a healthier and more resilient world by ensuring access to healthcare for the world’s poorest people and focusing on the development of cancer treatments infant. Integrated into the company’s Play to Win commercial strategy, Sanofi’s societal commitment will continue the fight against infectious diseases such as sleeping sickness and poliomyelitis, while accelerating its objectives to reduce the environmental impact of its products and its global operations. Key to addressing the global challenges facing society are its employees, who each have a role to play in building a diverse and inclusive workplace.
To become an issuer of sustainable finance instruments, Sanofi has put in place a dedicated Sustainability Bond Framework, designed as a living document to enable future bond issuances in a sustainability related format.
The Sustainability Bond Framework is aligned with the ICMA Sustainability Bond Principles (2020) and received a second-party opinion from ISS ESG.
Proceeds from the bond issue will be used for general corporate purposes.
The transaction was led by Morgan Stanley and Natixis CIB as Global Coordinators & Sustainability-Linked Structuring Advisors and Barclays, MUFG and RBC Capital Markets, all as Joint Active Bookrunners.
We are an innovative global healthcare company driven by one purpose: we pursue the miracles of science to improve people’s lives. Our team, present in over 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially game-changing treatment options and life-saving vaccine protection to millions of people around the world, while placing sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Eva Schäfer-Jansen | + 33 7 86 80 56 39 | [email protected]
Arnaud Delepine | + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt | + 33 6 40 56 92 21 | [email protected]
Felix Lauscher | + 1 908 612 7239 | [email protected]
This communication does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the titles. laws of such state or jurisdiction. The Securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) and may not be sold in the United States absent registration or an exemption from registration under the Securities Act.
This communication is addressed to and is directed only at persons from member states of the European Economic Area (“EEA”) who are qualified investors within the meaning of Article 2(e) of Regulation (EU) 2017/ 1129, as amended (the “Prospectus Regulation”).
MiFID II Professional/ECP Only – Manufacturer target market (MiFID II product governance) is Eligible Counterparties and Professional Clients only (all distribution channels). No EU PRIIPs Key Information Document (KID) has been prepared as the securities will not be available for retail trade in the EEA.
UK MiFIR/ECP Professionals Only – The target market for Manufacturers (UK MiFIR Product Governance) is Eligible Counterparties and Professional Clients only (all distribution channels). No Key Information Document (KID) for UK PRIIPs has been prepared as the securities will not be available at retail in the UK.
This communication may only be communicated in France to qualified investors as defined and in accordance with Article 2(e) of the Prospectus Regulation and Articles L.411-1 and L.411-2 of the French Code. monetary and financial.
This communication does not constitute an offer of the securities to the public in the United Kingdom. This communication is being distributed and directed only to (i) persons located outside the United Kingdom, (ii) persons who have professional experience in investment matters falling under Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (iii) persons who are high net worth entities falling within section 49(2)(a) to (d) of the Order, or (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment activity to which this communication relates will only be available and engaged with relevant persons. Any person who is not a Relevant Person should not act or rely on this document or its contents.
Sanofi forward-looking statements
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations regarding future financial results, events, operations, services, development and potential of products, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. , which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. These risks and uncertainties include, among others, uncertainties inherent in research and development, future clinical data and analyses, including post-marketing, decisions of regulatory authorities, such as the FDA or EMA, regarding the whether and when to approve any drug, device or biologic that may be filed for these product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of these product candidates, the fact that product candidates, if approved, may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to enter into related transactions and/or obtain regulatory approvals, intellectual property risks and any pending litigation or future partner and the ultimate outcome of such litigation, prevailing exchange rate and interest rate trends, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors and other business partners, and the financial condition of any of them, as well as on our employees and on the global economy as a whole. together. Any material effect of COVID-19 on any of the above may also adversely impact us. This situation is changing rapidly and additional impacts may arise that we are not currently aware of and may exacerbate other previously identified risks. Risks and uncertainties also include uncertainties discussed or identified in public filings with the SEC and AMF by Sanofi, including those listed under “Risk Factors” and “Caution Regarding Forward-Looking Statements” in the Sanofi’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021. Except as required by applicable law, Sanofi undertakes no obligation to update or revise any forward-looking information or statements. Sanofi does not undertake to update the above information or forward-looking statements subject to its obligations under applicable regulations, including article 223-1 et seq. Rregulation general of the AMF.